Patents by Inventor Yatin R. Gokarn
Yatin R. Gokarn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11607451Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: GrantFiled: March 12, 2013Date of Patent: March 21, 2023Assignee: Amgen Inc.Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, Jr., David Brems, Susan Irene Hershenson
-
Publication number: 20200392220Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.Type: ApplicationFiled: February 21, 2020Publication date: December 17, 2020Applicant: Genentech, Inc.Inventors: Yatin R. GOKARN, Timothy J. KAMERZELL, Megan LI, Mary CROMWELL, Hong LIU
-
Publication number: 20180171004Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.Type: ApplicationFiled: July 24, 2017Publication date: June 21, 2018Inventors: Yatin R. GOKARN, Timothy J. KAMERZELL, Megan LI, Mary CROMWELL, Hong LIU
-
Publication number: 20170368170Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention farther provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: September 7, 2017Publication date: December 28, 2017Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160367666Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160367665Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that arc suitable for veterinary and human medical use, The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 9, 2016Publication date: December 22, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160362485Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that arc suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 5, 2016Publication date: December 15, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160362486Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 8, 2016Publication date: December 15, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160362484Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 3, 2016Publication date: December 15, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160339102Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: August 4, 2016Publication date: November 24, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160319011Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: July 19, 2016Publication date: November 3, 2016Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20160251422Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.Type: ApplicationFiled: November 25, 2015Publication date: September 1, 2016Inventors: Yatin R. GOKARN, Timothy J. KAMERZELL, Megan LI, Mary CROMWELL, Hong LIU
-
Patent number: 9226961Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.Type: GrantFiled: October 4, 2013Date of Patent: January 5, 2016Assignee: Genentech, Inc.Inventors: Yatin R. Gokarn, Timothy J. Kamerzell, Megan Li, Mary Cromwell, Hong Liu
-
Publication number: 20140099301Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.Type: ApplicationFiled: October 4, 2013Publication date: April 10, 2014Applicant: Genentech, Inc.Inventors: Yatin R. Gokarn, Timothy J. Kamerzell, Megan Li, Mary Cromwell, Hong Liu
-
Publication number: 20130273066Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: March 12, 2013Publication date: October 17, 2013Inventors: Yatin R. GOKARN, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20130273067Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: March 12, 2013Publication date: October 17, 2013Inventors: Yatin R. GOKARN, Eva KRAS, Richard Louis REMMELE, JR., David BREMS, Susan Irene HERSHENSON
-
Publication number: 20120028877Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: July 21, 2011Publication date: February 2, 2012Applicant: Amgen Inc.Inventors: Yatin R. GOKARN, Eva Kras, Richard Louis Remmele, JR., David Brems, Susan Irene Hershenson
-
Publication number: 20110226650Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.Type: ApplicationFiled: December 20, 2010Publication date: September 22, 2011Applicant: Genentech, Inc.Inventors: Yatin R. Gokarn, Timothy J. Kamerzell, Megan Li, Mary Cromwell, Hong Liu
-
Publication number: 20080311078Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.Type: ApplicationFiled: June 8, 2006Publication date: December 18, 2008Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, David Brems, Susan Irene Hershenson
-
Publication number: 20040127537Abstract: A parenterally deliverable pharmaceutical composition comprises a water soluble parecoxib salt, in dissolved and/or solubilized form in a solvent liquid that comprises water and one or more nonaqueous solubilizer(s). Valdecoxib formed by conversion of parecoxib is solubilized by the nonaqueous solubilizer(s), which are substantially inert with respect to such conversion. The composition has parecoxib salt stabilizing means for inhibiting precipitation of parecoxib free acid. The composition is storage stable and is suitable for parenteral administration to treat a COX-2 mediated condition or disorder.Type: ApplicationFiled: June 18, 2003Publication date: July 1, 2004Inventors: Yatin R. Gokarn, Richard Schartman